Mankind Pharma faces Rs 183 crore tax demand, plans to appeal

Mankind Pharma has received tax demand orders from the Income Tax Department for Assessment Years (AY) 2014-15 to 2017-18, amounting to ₹183.11 crore, including interest. The demand arises from the disallowance of various expenditures under Section 37(1) of the Income-tax Act, 1961.

According to a regulatory filing, the orders were issued by the Office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi.

The orders for AY 2014-15 and 2016-17 were dated March 24, 2025, while those for AY 2015-16 and 2017-18 were dated March 25, 2025. The company received the orders through the IT portal on March 28, 2025.

Mankind Pharma has said that it believes the tax demand is not legally justified and that it has strong factual and legal grounds to challenge the order. The company also asserted that the order is not expected to have any material impact on its financials or operations.

The pharmaceutical firm plans to appeal the order under applicable laws. Investors will be monitoring the situation closely as the company navigates this tax challenge.

Related Posts

Diabetic drug metformin found to act on brain

NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

Hetero debuts semaglutide generic in emerging markets

New Delhi: Hyderabad-based drugmaker Hetero has announced the launch of its generic semaglutide portfolio in emerging international markets. In a phased global push, the company plans to roll out its…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Diabetic drug metformin found to act on brain

Diabetic drug metformin found to act on brain

Hetero debuts semaglutide generic in emerging markets

Hetero debuts semaglutide generic in emerging markets

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Stem cell therapy for autism illegal: NMC advisory

Stem cell therapy for autism illegal: NMC advisory

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework